RGD-modified pH-sensitive liposomes for docetaxel tumor targeting

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Drug Delivery Systems

Background:

• Phosphatidylethanolamine-based pH-sensitive liposomes (PLPs) are effective for delivering therapeutic molecules into tumor cells.
• Targeted drug delivery systems are crucial for enhancing cancer treatment efficacy and minimizing side effects.

Purpose of the Study:

• To develop and characterize arginine-glycine-aspartic acid (RGD) peptide-modified pH-sensitive liposomes (PLPs) for improved docetaxel delivery.
• To evaluate the in vitro and in vivo performance of RGD-modified PLPs for enhanced tumor targeting and cytotoxicity.

Main Methods:

• Docetaxel and coumarin-6 loaded PLPs were prepared using the thin-film dispersion method.
• Characterization included particle size, polydispersity, zeta potential, and drug encapsulation efficiency.
• In vitro cytotoxicity and cellular uptake studies were performed on MCF-7, HepG2, and A549 cancer cell lines.
• In vivo tumor accumulation was assessed using NBD-labeled liposomes in xenograft mouse models.

Main Results:

• RGD-modified PLPs exhibited particle sizes between 129-146 nm.
• In vitro studies showed RGD-PLPs had higher cytotoxicity and cellular uptake compared to non-coated PLPs.
• In vivo imaging revealed enhanced fluorescence and accumulation of RGD-PLPs in tumors, indicating improved targeting.

Conclusions:

• RGD-modified pH-sensitive liposomes show potential as a drug delivery system for controlled release and targeted tumor accumulation.
• This approach may enhance the effectiveness of docetaxel-based cancer treatments.